BMS cuts costs to drive growth
Bristol-Myers Squibb (BMS) has cut $400 million in annual expenses over the last two years in order to boost its R&D pipeline and achieve sales and earnings growth beginning in 2007.
Bristol-Myers Squibb (BMS) has cut $400 million in annual expenses over the last two years in order to boost its R&D pipeline and achieve sales and earnings growth beginning in 2007.
India's clinical research industry is currently valued at $100 million (€83 million) and is almost doubling each year, reflecting the shifting focus of the pharmaceutical outsourcing industry to Asia.
Cardinal Health, the world's largest supplier of services to the healthcare industry, is building its first tablet coating facility to offer its pharmaceutical clients a range of innovative delivery systems that target the oral drug delivery market.
Tripos has announced the latest details in its cost cutting strategy, which is expected to result in job losses, principally in the UK. The cuts come as Tripo's four-year $90 million file enrichment project with Pfizer draws to a close.
Actavis Group has announced the company has acquired the human generics business of Alpharma, making the international generic pharmaceuticals company one of the five largest companies in generic pharmaceuticals worldwide in terms of revenue.
In the same week that saw Novartis threaten its planned merger with Berna Biotech, Dutch biotech company Crucell has signed three new licensing agreements for its PER.C6 and STAR manufacturing technologies.
Scientists have described the cellular structure of a protein that plays a critical role in drug resistance, which may open up new avenues for laboratory research that may result in the enhancement of existing therapies for Cancer and infectious diseases.
Fine chemical and pharmaceutical intermediate manufacturers may be affected by supply disruptions due to ongoing UK shortages of natural gas. Price spikes in gas are becoming both higher and more frequent in the UK.
Artel, has announced that the International Organisation for Standardisation (ISO) has approved the use of the photometric method for liquid delivery performance verification, which emphasises the role photometry has to play for drug discovery...
Cresset Biomolecular Discovery has launched a technology that identifies the 3-dimensional bound conformation of hits and potential drugs in a biological target, assisting scientists involved in ion channel research.